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Revisiting Bevacizumab 1 Cytotoxics Scheduling Using
Mathematical Modeling: Proof of Concept Study in
Experimental Non-Small Cell Lung Carcinoma
Diane-Charlotte Imbs1†, Raouf El Cheikh1†, Arnaud Boyer1,2, Joseph Ciccolini1, Celine Mascaux1,2, Bruno Lacarelle1,
Fabrice Barlesi1,2, Dominique Barbolosi1 and Sebastien Benzekry3,4*
Concomitant administration of bevacizumab and pemetrexed-cisplatin is a common treatment for advanced nonsquamous
non-small cell lung cancer (NSCLC). Vascular normalization following bevacizumab administration may transiently enhance
drug delivery, suggesting improved efficacy with sequential administration. To investigate optimal scheduling, we conducted
a study in NSCLC-bearing mice. First, experiments demonstrated improved efficacy when using sequential vs. concomitant
scheduling of bevacizumab and chemotherapy. Combining this data with a mathematical model of tumor growth under
therapy accounting for the normalization effect, we predicted an optimal delay of 2.8 days between bevacizumab and
chemotherapy. This prediction was confirmed experimentally, with reduced tumor growth of 38% as compared to concomitant
scheduling, and prolonged survival (74 vs. 70 days). Alternate sequencing of 8 days failed in achieving a similar increase in
efficacy, thus emphasizing the utility of modeling support to identify optimal scheduling. The model could also be a useful
tool in the clinic to personally tailor regimen sequences.
CPT Pharmacometrics Syst. Pharmacol. (2017) 00, 00; doi:10.1002/psp4.12265; published online on 0 Month 2017.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Bevacizumab is usually administered concomitantly
with cytotoxics. However, studies have demonstrated
that bevacizumab before cytotoxics yields better effi-
cacy by improving drug uptake, due to a transient
phase of vascular normalization following bevacizumab
uptake. Determining the best sequence is challenging
and could be patient-dependent.
WHAT QUESTION DID THIS STUDY ADDRESS?
 What is the optimal schedule for the administration
of bevacizumab and pemetrexed-cisplatin doublet in
NSCLC?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 This study shows, using experimental settings and
mathematical modeling, that administration of bevacizu-
mab 3 days before cytotoxics yields better efficacy and
overall survival compared to concomitant, cytotoxics
before bevacizumab, and cytotoxics alone treatments. It
also provides a validated model that could be used to
individualize combination regimen in the clinic.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 This study demonstrates that simplified modeling could
help to address the issue of finding and personalizing
optimal sequences when combining anticancer treatments.
When combined with chemotherapy, antivascular endothe-
lial growth factor-A bevacizumab achieved improved overall
survival (OS) and/or progression-free survival in multiple
phase III trials for several types of solid tumors.1–7
Although the main effect of bevacizumab is the disruption
of the vascularization, increased efficacy with combined
administration of cytotoxic agents could also result from
transitory vascular normalization, a paradoxical effect of
anti-angiogenics.9–12 Indeed, preclinical and clinical studies
have shown that bevacizumab induces transient changes in
the vascular architecture.9,13,14 Although the unaltered
tumor vasculature is tortuous, chaotic, and poorly func-
tional,15 bevacizumab prunes and remodels tumor vessels
to make them resemble normal tissues in terms of structure
and function.10,16 It also proved to induce a more homoge-
neous distribution of cytotoxics in actively proliferating areas
of tumor vessels.17 Therefore, determining alternate sched-
uling with bevacizumab could improve efficacy.9
In line with these hypotheses, Dickson et al.18 showed
that administrating topotecan after bevacizumab to neuro-
blastoma tumor-bearing mice resulted in reduced tumor
growth as compared to concomitant administration. Another
recent study showed that bevacizumab followed 24 hours
later by paclitaxel potentiated its antitumor activity in an
ovarian cancer model.17 At bedside, Avallone et al.19
showed that administering bevacizumab 4 days prior to
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chemotherapy in patients with locally advanced rectal can-
cer led to better OS and progression-free survival com-
pared to concomitant administration. Although promising,
most attempts to revisit bevacizumab scheduling have been
made on an empirical basis and a trial-and-error mode.
Mathematical modeling could help assisting experimental
and clinical studies to better understand the combined
effects of anti-angiogenics and cytotoxics on tumor
growth.20,21 Building on the Hahnfeldt et al.22 model for the
effect of anti-angiogenic monotherapy, Wilson et al.23 devel-
oped a model to quantify the dynamics of interaction
between tumor growth, vasculature generation, and anti-
angiogenic treatment. They demonstrated a possible syner-
gistic interaction between sunitinib and irinotecan.23
Recently, Hutchinson et al.24 developed a model of vascular
tumor growth and normalization from breast cancer mice
treated with bevacizumab alone. Still in breast cancer, our
team tested multiple regimens for combining bevacizumab
and paclitaxel. Experimental results combined with mathe-
matical simulations suggested that scheduling bevacizumab
2 days before paclitaxel could improve antitumor efficacy
and reduce metastatic spreading.25
The aim of the present modeling and experimental study
was to assess predictions of a semimechanistic mathematical
model in terms of the optimal sequence of administration for
the combination of bevacizumab and pemetrexed-cisplatin in
non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS
Mice experiments
Cell lines. Human NSCLC cells H460 stably transfected
with luciferase (H460 Luc1) were purchased from Perkin
Elmer, France. This BioWare light producing cell line was
derived from the H460 human adenocarcinoma by stable
transfection of the North American firefly gene expressed
from the SV40 promoter. Cells were cultured per the manu-
facturer’s recommendation at 378C in a humidified atmo-
sphere with 5% CO2. H460 Luc1 cells were regularly
authenticated based on viability, growth, morphology, and in
vitro bioluminescence measuring.
For experiment two, tumor growth monitoring was carried
out by fluorescence. Therefore, H460 Luc1 cells were
transfected with tdTomato gene using pPGK-tdTomato lenti-
viral plasmid lentiviral plasmid as vector kindly provided by
Dr Valerie Le Morvan (Institut Bergonie, Bordeaux, France).
Forty-eight hours after transfection, blasticidine (10 mg/mL)
was added and selection was maintained for 2 weeks.
Resulting H460 Luc1 dtTomato1 cells were regularly
authenticated by microscopy based on viability, growth,
morphology, and in vitro fluorescence monitoring.
Animal experiments
All experiments were approved by the local ethical committee
of our institution and registered as #2015110616255292
(French Ministère de l’Education Nationale, de l’Enseignement
Superieur et de la Recherche) prior to starting the experi-
ments. Guidelines for animal welfare in experimental oncology
as recommended by European regulations were followed.
Pathogen-free, immunocompromised 6-week-old female
Swiss nude mice (Charles River Laboratories, France) were
kept in a sterile environment for 2 weeks upon reception.
Mice were maintained in sterilized filter-topped cages and a
sterile thermostatic cabinet throughout the study. Signs of dis-
tress, decreased physical activity, and any behavioral change
were monitored daily. Bodyweights were monitored twice
weekly as a surrogate marker for general toxicity. Water was
supplemented with paracetamol (eq. 80 mg/kg/day) to prevent
any disease-related pain. Animals showing signs of distress,
pain, cachexia (i.e., loss of 10% of body weight), and tumor
mass over 2 g (i.e., 2 cm3) were euthanized.
Xenografting
H460 Luc1 (and tdTomato1 for the second experiment)
cells were trypsinized, counted, centrifuged (5 minutes,
1,000 g) and washed twice with sterile phosphate-buffered
saline. Cells were resuspended in Roswell Park Memorial
Institute-1640 with 60% Matrigel (BD Sciences, France)
and maintained in ice-cooled conditions until engraftment.
A volume of 50 mL containing 80,000 cells (experiment one)
and 120,000 cells (experiment two) was injected ectopically
in the left flank of each mouse while under anesthesia. In
total, 132 tumor-bearing mice were required to perform
both experiments. However, overall, 139 mice were initially
xenografted, to ensure that eventually at least 48 (experi-
ment one) 1 84 mice (experiment two) presenting positive
and measurable tumors could be used, considering an esti-
mated 5% of failure rate during the grafting procedure.
Bioluminescence imaging
In experiment one, monitoring of primary tumor growth
started 1 week after engraftment. Acquisitions started 12
minutes after firefly D-Luciferin (Perkin Elmer, 300 mg/kg)
i.p. injection to reach a plateau in bioluminescence signal-
ing.26 Acquisition and data processing were performed
using the IVIS spectrum imager equipped with the Living
Image 4.2 software (Perkin Elmer). Imaging was performed
twice per week. All imaging was performed in anesthetized
animals (sevoflurane).
Fluorescence imaging
In experiment two, imaging was performed twice in anes-
thetized animals (sevoflurane). Acquisition (excitation:
554 nm, emission: 581 nm), and data processing were per-
formed using the IVIS spectrum imager equipped with the
Living Image 4.2 software.
Experiment one treatments
In experiment one, 47 xenografted mice were randomized
into 4 treatment arms (Supplementary Figure S1a): control
(saline injection, n 5 12), sequential treatment with bevacizu-
mab administered 4 days before pemetrexed-cisplatin (“beva
then chemo 4 days,” n 5 12), sequential treatment arm with
bevacizumab administered 4 days after pemetrexed-cisplatin
(“chemo then beva 4 days,” n 5 11), and a concomitant treat-
ment arm (“beva 1 chemo,” n 5 12). Treatment started 17
days after xenograft. Doses in each arm were 20 mg  kg21,
100 mg  kg21 and 3 mg  kg21 for bevacizumab, peme-
trexed, and cisplatin, respectively. All treatments, including
saline, were administered by i.p. route for three 14-day cycle.
All animals were euthanized on day 76 post-xenografts.
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Experiment two treatments
The second experiment was performed with model-based
changes both in scheduling and sample sizes. In experi-
ment two, 77 xenografted mice were randomized into 5
treatment arms (Supplementary Figure S1b): control
(saline injection, n 5 15), sequential treatment with bevaci-
zumab administered 3 days (see next section below) before
pemetrexed-cisplatin (“beva then chemo 3 days,” n 5 16),
sequential treatment with bevacizumab administered 8 days
before pemetrexed-cisplatin (“beva then chemo 8 days,”
n 5 15), concomitant (“beva 1 chemo,” n 5 15), and peme-
trexed and cisplatin alone (chemo, n 5 15). The adminis-
tered doses in each arm were 20 mg  kg21; 100 mg  kg21
and 3 mg  kg21 for bevacizumab, pemetrexed, and cis-
platin, respectively. All treatments were administered by i.p.
route. As for experiment one, 3 cycles (14 days cycle) were
administered, starting on day 14 after xenograft. All animals




The tumor size at time t is denoted V tð Þ. The function C tð Þ
combines plasma concentration of pemetrexed and cisplatin
(C tð Þ5Cpem tð Þ1Ccis tð ÞÞ. The function A tð Þ represents the
plasma concentration of bevacizumab. Pharmacokinetic
time courses for bevacizumab, cisplatin, and pemetrexed
were modeled each by a one-compartment model with
absorption compartment and pharmacokinetic parameters
from the literature.27–29 Supplementary Figure S2a
depicts the concentration profiles for each treatment. A
scheme describing the pharmacodynamic model is given in
Figure 1. It is based on the following hypotheses:
• (H1) Without treatment the tumor size kinetics follow a Gompertzian
growth governed by parameters a (proliferation rate of the tumor
cells) and b (rate of exponential decrease of the tumor relative
growth rate).30
• (H2) Cytotoxics act by targeting a fraction of the tumor size (log-kill
effect).31 This effect is driven by the parameter c.
• (H3) There is a delay between the administration time of cytotoxics
and their effects on the tumor. Tumor cells pass through different
stages, characterized by different degree of damages, before they
get eliminated.32 The transfer rate between these stages is denoted
k .
• (H4) In the absence of data monitoring, the state of the tumor vas-
culature and the anti-angiogenic effect of bevacizumab are not
explicitly modeled.
• (H5) Bevacizumab increases the drug’s delivery by improving the
vasculature quality Q.33 The dynamics of this improvement is
assumed to follow the bevacizumab concentration, delayed by a
time shift s for the normalization to occur. The magnitude of the
improvement is controlled by a parameter d.The above assumptions
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The initial size V0 was set to 7.04 3 10
6 photons/second,
considering that 80,000 cells were injected (experiment
one) and a previously established conversion ratio of Vc5
1 cell  88 photons/second.34
Statistical model and parameters estimation
For a description of the inter-animal variability, we used the
nonlinear mixed-effects statistical framework.35 It consists in
assuming a distribution of the parameters within the animal
population, taken here to be log-normal for each parameter.
Importantly, these were the same for all treatment groups.
The structural model above depends on six parameters
(a; b; c; d; s; kÞ: After an initial sensitivity analysis showing
that not all of these parameters were identifiable from our
dataset (Supplementary Methods), we reduced this to the
four parameters (a; b; d; sÞ: These parameters were then
estimated by adapting the result of likelihood maximization
performed with the Monolix software (Lixoft, version 2016R1)
using visual assessment of the goodness-of-fit (visual predic-
tive checks) and consideration of the root mean squared
error. See Supplementary Methods and Supplementary
Figures S3-S6 for details. Values of the resulting parameters
are reported in Table 1. Model simulations were performed
using Matlab software.
Statistical analysis
Statistical analyses were performed using R software 3.3.2
(R Core Team, 2016). Intergroup differences in tumor
growth were tested by nonparametric Kruskal-Wallis tests,
should the data not meet the assumptions for one-way
analysis of variance. Further between-group comparisons
Figure 1 Scheme of the structural mathematical model.




were performed either by Dunn’s multiple comparison tests
when treatment groups were compared with the control
group, or by Nemenyi post-hoc tests with Tukey approxima-
tion for pairwise multiple comparison between groups. Sur-
vival analysis was done using Kaplan-Meier analysis.
Intergroup differences in survival were tested for signifi-
cance by the log-rank tests. Owing to sample size, a P val-
ue< 0.05 was considered statistically significant.
RESULTS
Administering bevacizumab before pemetrexed 1
cisplatin improved efficacy and median of survival
Experiment one efficacy. Monitoring of tumor growth for
experiment one is shown in Figure 2a. At the end of the
treatment phase (day 53), mean tumor sizes (expressed in
3 109 photons/second (p/s)) were 16.9 6 3.7 (control),
19.2 6 3.4 (“chemo then beva 4 days”), 15.4 6 2.5
(“beva 1 chemo), and 6.9 6 2.1 (“beva then chemo 4 days”).
A statistical difference was found between the groups
(P 5 0.012). Further Dunn’s multiple comparison tests evi-
denced a significant difference between the sequential
administration “beva then chemo 4 days” and control arms
(59% tumor growth reduction, P 5 0.047). Conversely, con-
comitant “beva 1 chemo” and reversed “chemo then beva 4
days” groups had modest effects on tumor growth inhibition
(9% tumor reduction (P 5 0.98) and 13% higher tumor size
(P 5 1) as compared with the control group, respectively).
The sequential administration of “beva then chemo 4 days”
also confirmed its superiority in efficacy when compared
with other treatment groups (55% tumor reduction, almost
reaching significance compared to “beva 1 chemo”
(P 5 0.071) and 64% tumor reduction compared to “chemo
then beva 4 days” (P 5 0.0073)). All mice in the control
group had to be euthanized at day 53.
At study conclusion (day 67; i.e., 18 days after all treat-
ments stopped), mean tumor growth were 19.4 6 3.7
(“chemo then beva 4 days”), 15.7 6 2.7 (“beva 1 chemo”)
and 10.0 6 2.0 (“beva then chemo 4 days”). The sequential
administration in the “beva then chemo 4 days” arm had
the lowest mean tumor size compared with the other
remaining groups (36% lower than concomitant in the
“beva 1 chemo” arm and 49% lower than reversed in the
“chemo then beva 4 days” arm), although not statistically
significant (P 5 0.42 and 0.13, respectively).
Survival curves for experiment one are displayed in
Figure 2b. The median survival times were 39 days (con-
trol), 49 days (“chemo then beva 4 days”), 55 days (“beva 1
chemo”), and 67 days (“beva then chemo 4 days”). A log-
Table 1 Population parameters and interanimal variabilities estimates for experiment one data
Parameters Description Units Estimates RSEa (%) IAVb %
a Proliferation rate Day21 0:767 8 8:62
b Exponential decay rate of the relative tumor growth
rate (Gompertz model)
Day21 0:037 10 57:3
c Baseline effect of the chemotherapy (mg/g)21.day21 1 2 2
d Cytotoxics efficacy improvement following
vascular normalization
(mg/mL)21 1; 200 36 0
s Delay parameter for dynamics of Q Day 2 20 10
k Delay of the tumor cell loss following chemotherapy Day21 0:3 2 2
R Exponential error parameter 2 0:951 4 2
IAV, interanimal variabilities; RSE, relative standard error.
Values of the parameters corresponding to the adapted fit. See Supplementary Methods for details on the estimation procedure.
aRSE is a measure of the precision of the parameter estimates, expressed as coefficient of variation (CV%).
bThe IAV is the standard deviation x estimated using Monolix software.
(a) (b)
Figure 2 Efficacy and Kaplan-Meier survival curves of experiment one. (a) Mean tumor growth curves for the four treatment arms
of experiment one. Signs above curves indicate statistically significant difference with the control arm (Student’s t test, P< 0.05).
(b) Kaplan-Meier plot of the overall survival for the four treatment arms of experiment one.
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rank test showed a significant difference between all groups
(P< 0.0001). Further log-rank tests showed that each treat-
ment group was significantly different than the control arm
(P< 0.001). Moreover, the sequential administration in the
“beva then chemo 4 days” arm had greater survival median
and was significantly different than concomitant in the
“beva 1 chemo” (P 5 0.0485) and reversed in the “chemo
then beva 4 days” arms (P 5 0.0496). Conversely, no signif-
icant difference was observed between the “beva 1 chemo”
and the “chemo then beva 4 days” arms (P 5 0.631).
Mathematical modeling predicted an optimal time delay
of 3 days between the administration of bevacizumab
and pemetrexed 1 cisplatin
The selected model is a modified version of the Gompertz
model with a delay in the treatment effects32 and inclusion of
a dynamic variable Q accounting for the vasculature quality
and, thus, the normalization effect. See the Materials and
Methods section for a detailed description of the model equa-
tion, data fit, and parameters’ estimation method. Population
analysis yielded the median parameter and interanimal vari-
ability estimates reported in Table 1 with good relative stan-
dard errors. Goodness-of-fit was assessed by visual
predictive check plots (Figure 3a-d), which demonstrated a
good agreement between the model simulations and the
experimental data (see residual analysis in Supplementary
Figure S7). Individual simulations also demonstrated the
ability of our model to reproduce tumor growth dynamics for
each mouse (Supplementary Figure S8).
The model with parameters calibrated on the experimen-
tal data allowed us to perform simulations varying the time
lag between the administrations of bevacizumab and the
pemetrexed-cisplatin doublet. The criterion for quantification
of efficacy was the area under the tumor growth curve.
Delays ranging from 1–10 days were tested. Simulation
results showed that a 2.8-days delay between bevacizumab
and chemotherapy achieved greater reduction in tumor
sizes, with a difference of 76.8% in tumor size as compared
with concomitant scheduling (Figure 4a-c). Our quantifica-
tion of the normalization dynamics also predicted that a
delay of 8 days would perform substantially worse, with a
difference of only 54.3% compared with concomitant admin-
istration (Figure 4c). Quantification of the interanimal vari-
ability of the model parameters using our population
approach allowed to simulate the resulting interanimal vari-
ability of the optimal interdrug administration gap. The opti-
mal gap ranged from 0–10 days with median of 2.8 days
and standard deviation of 1.84 days (Figure 4d).
(a) (b)
(c) (d)
Figure 3 Visual predictive check for experiment one population analysis. (a–d) Visual predictive check plots. Circles: experimental
data. Stars with broken lines: median data. Solid lines: tumor growth simulated curves using median parameter values, dashed lines:
95% intervals for interanimal variability, generated from the simulation of 1,000 virtual animals with parameters distributed according to
the distribution estimated by the mixed-effects fit. Beva, bevacizumab; Chemo, chemotherapy.




Validation of the optimal delay predicted by the model
To test the predictions from the mathematical model, we
designed a new experiment that implemented the above-
mentioned schedules (3 and 8 day lag for sequential
administrations of “beva then chemo”).
Tumor growth for experiment two is shown in Figure 5a.
At the end of the treatment phase (day 54), mean tumor
size (expressed in p/s) were 12,567 6 2,461 (control),
8,692 6 543 (“beva then chemo 8 days”), 8,446 6 1,253
(chemo), 7,486 6 1,106 (“beva 1 chemo”), and 4,626 6 868
(“beva then chemo 3 days”). A statistically significant differ-
ence between all arms was obtained (P 5 0.0016). Further,
Dunn’s multiple comparison tests confirmed the superiority
of the sequential administration “beva then chemo 3 days,”
and showed a statistically significant difference in efficacy
between the “beva then chemo 3 days” arm and the control
arm (63% of tumor growth reduction (P 5 0.002)). Other
treatment sequences led to more modest effects on tumor
growth as compared with the control arm. Furthermore,
mean tumor size for the sequential administration in the
“beva then chemo 3 days” arm was markedly lower and
almost reached significant difference compared to all other
treatment arms (i.e., 38% compared with concomitant
“beva 1 chemo” (P 5 0.072), 47% tumor growth reduction
as compared with “beva then chemo 8 days” (P<0.001),
and 45% compared with the chemo group (P 5 0.016)).
At the end of the experiment (day 67; i.e. 9 days after all
treatment stopped), a statistically significant difference was
found between the four remaining arms (P 5 0.015). Fur-
ther, Dunn’s multiple comparison tests showed that “beva
then chemo 8 days” was significantly different than the opti-
mized “beva then chemo 3 days” group (48% tumor growth
reduction, P 5 0.007). However, no more statistically signifi-
cant difference was evidenced among the other treatment
arms.
The median survival times were 48 days (control), 54
days (chemo), 67 days (“beva then chemo 8 days”), 70
days (“beva 1 chemo”), and 74 days (“beva then chemo 3
days”), as presented in Figure 5b. A log-rank test showed
a statistically significant difference between each treatment
arm and the control arm (P< 0.0001). Consistently with our
mathematical model predictions, further log-rank tests
showed a statistically significant difference between the
“beva then chemo 3 days” and “beva then chemo 8 days”
arms (P 5 0.0056). Conversely, the difference did not reach
statistical significance between the sequential “beva then
(a) (b)
(c) (d)
Figure 4 Data-informed modeling simulations of various gaps between bevacizumab and pemetrexed-cisplatin administrations.
(a) Median tumor growth curves. (b) Simulations of the tumor growth using different time lags between the administration of bevacizu-
mab and pemetrexed-cisplatin (“beva then chemo”). The red curve corresponds to a time lag of 3 days. (c) Area under the tumor
growth curve (AUC) as a function of the time lag. (d) Interanimal variability on the optimal lag time between bevacizumab and chemo-
therapy (2.8 6 1.84 days, median 6 SD).
Revisiting Bevacizumab 1 Cytotoxics Scheduling
Imbs et al.
6
CPT: Pharmacometrics & Systems Pharmacology
chemo 3 days” and concomitant “beva 1 chemo” arms
(P 5 0.32).
DISCUSSION
Bevacizumab induces a transient phase of vascular normal-
ization. If correctly identified, this could increase drug deliv-
ery and improve treatment outcome. In this study, we
proposed an integrative strategy that combined experi-
ments on NSCLC tumor-bearing mice and mathematical
modeling to explore and validate improved scheduling of
the sequential administration of bevacizumab with cyto-
toxics. In our first experiment, our data confirmed the bene-
fits, in terms of survival and efficacy, of administering
bevacizumab before cytotoxics. To analyze these data, we
developed a semimechanistic mathematical model with a
critical component quantifying the dynamics of vascular
normalization. Model parameters were estimated using a
nonlinear mixed effects approach and simulations predicted
that giving bevacizumab 3 days before cytotoxics would
yield better efficacy. Subsequent experiments confirmed the
superiority of this optimized sequence compared with other
sequential and concomitant administrations. This proves
that beyond a simple shift to sequential administration to
achieve better efficacy, the precise timing of the administra-
tion of each drug does matter and that mathematical
modeling may help to identify optimized alternate schedul-
ing that would require too much resources to be explored
empirically.
Human NSCLC H460 cells are a canonical model when
performing experimental therapeutics studies in lung cancer.
In this respect, following previously published experimental
studies, we have chosen the H460 model as a paradigm for
mimicking NSCLC tumors.36–38
Compared to our previous studies,21,24 the mathematical
model presented here was simplified to focus on a minimal
number of equations and parameters. We abandoned a
more mechanistic description of the vasculature quality in
terms of stable and unstable vessels to the benefit of a
more phenomenological but more parsimonious and robust
model that implements normalization in terms of a simple
delay from the bevacizumab concentration.
Mean tumor growth curves obtained in experiment one
highlight the high interanimal variability observed within
each treatment group (Figure 2a). This variability can par-
tially explain the high residual variability (R 5 0.951). More-
over, comparing standard errors of tumor growth data
between experiments one and two emphasizes the higher
variability of bioluminescence measurements compared to
fluorescence imaging. A likely explanation for this discrep-
ancy is the interanimal variability of pharmacokinetics of
luciferin used as a tracer for bioluminescence.39
In experiment two, although differences in survival
between the “beva 1 chemo” and “beva then chemo 3 days”
groups did not reach statistical significance, median survival
was still larger in the latter than in the former (74 days vs.
70 days). Moreover, final tumor size was 38% smaller in
the “beva then chemo 3 days” as compared to the “beva 1
chemo” group. The P value of a Kruskal-Wallis test for this
difference was not below the arbitrarily level of 0.05, but was
close to it (P 5 0.072), thus still supporting superiority of the
“beva then chemo 3 days” group. We hypothesize that this
lack of statistical significance in our results is due to a limited
power of the study, itself linked to the restricted number of
animals per group for ethical constraints.
Several studies have already explored alternate sequen-
ces for administering anti-angiogenics with other drugs,
with sometimes contradictory results. Rocchetti et al.40
found that giving bevacizumab after targeted therapy in
tumor-bearing mice yielded better efficacy. Recently, Hutch-
inson et al.24 inferred (using a mathematical model and
experimental data from breast cancer models) a vessel nor-
malization window beginning 15 days after the start of anti-
angiogenics which is a much larger optimal delay
compared to other studies.23,25 In addition, such lag-time
could hardly meet the requirements of clinical testing,
because bevacizumab is usually administered on a Q2W or
a Q3W basis at bedside. The optimal lag we identified in
our study is in line with other experimental studies that
explored the normalization window after bevacizumab or
(a) (b)
Figure 5 Efficacy and Kaplan-Meier survival curves of experiment two. (a) Mean tumor growth curve for the five treatment arms of
experiment two. Signs above curves indicate statistically significant difference with the control arm (Student’s t test, P<0.05).
(b) Kaplan-Meier plot of the overall survival for the five treatment arms of experiment two.




other anti-angiogenics administration, most of these report-
ing an optimal delay ranging between 2 and 5 days.18,33,41
In patients, Avallone et al.19 showed that giving bevacizu-
mab 4 days prior to chemotherapy yielded better efficacy
compared to concomitant administration.
Intriguingly, two clinical studies in NSCLC and metastatic
colorectal cancer showed reduced tumor drug delivery of
cytotoxic agents when administered 1 and 4 days after bev-
acizumab,42 which contrasts with our preclinical findings
and direct clinical observation of vessel normalization after
bevacizumab administration by means of interstitial fluid
pressure measurements and functional computed tomogra-
phy.43 More precisely, a study conducted on 10 patients
with NSCLC treated with a single dose of 15 mg/kg of bev-
acizumab followed by 11C labeled-docetaxel found a
decreased tumor uptake of the chemotherapy after 4
days.44 These findings were obtained on a small group,
with a different bevacizumab dose, no repeated cycle, and
a different chemotherapeutic drug than here, which alto-
gether might explain the discrepancy. Interestingly, in this
same study a wide interpatient variability was observed in
the reduction of perfusion and uptake of docetaxel. To this
regard, our mathematical model could be of help by charac-
terizing and quantifying the tumor response in a patient-
specific fashion and integrate relevant biomarkers of vessel
normalization into a predictive numerical tool for individually
optimized scheduling.
Together, these findings highlight the importance of drug
scheduling and advocate further studies to optimize sched-
uling of anti-angiogenic drugs. In this respect, our approach
in conducting experimental studies assisted by semime-
chanistic mathematical modeling proved to be efficient and
both time-effective and cost-effective. This proof-of-concept
study suggests that simplified modeling could help to
address the issue of finding the optimal dosing and sched-
uling of anticancer treatments to improve efficacy.
Critically, our model could be used in a biomarker-based
strategy for improving anti-angiogenic therapy. As observed
in Figure 4d, even in a homogenous controlled animal pop-
ulation, variability in the optimal gap was observed.
Although no predictive biomarker has yet been clearly vali-
dated with anti-angiogenics,45 our model parameters (pos-
sibly included in a broader modeling of metastatic
disease46) could be quantitatively linked to imaging data
and/or predictive circulating biomarkers acting as covari-
ates.47,48 Consequently, this would provide personalized
simulations of response to treatment allowing to individually
adapt the dose and timing in order to maximize the efficacy
and reduce the toxicity at the patient’s bedside.
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